2476-213X

Journal of Clinical Infectious Diseases & Practice
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Clin Infect Dis Pract 2022, Vol 7(5): 159

Colchicine and Covid-19: Could there still be Hope for this Old Low-Cost Drug?: Multicenter Observational Study in Hospitalized Patients

Elena Villamanan1*, Carmen Sobrino2, Carlos Carpio3, Carmen Mateos2, Yolanda Larrubia4, Ester Zamarrpon3, Eduardo Armada5, Almudena Castro5, Jesus Llorente4, Alicia Martinez4, Jorge Gomez-Cerezo6, Alicia Herrero2 and Rodolfo Alvarez-Sala7
1Pharmacy Department, Hospital Universitario La Paz, Institute for Health Research IdiPAZ, Medicine Department, Universidad Autonoma de Madrid, Spain
2Pharmacy Department, Hospital Universitario La Paz, Institute for Health Research IdiPAZ, Madrid, Spain
3Pulmonology Department, Hospital Universitario La Paz, Institute for Health Research IdiPAZ, Madrid, Spain
4Pharmacy Department, Hospital Universitario Infanta Sofia, Madrid, Spain
5Cardiology Department, Hospital Universitario La Paz, Institute for Health Research IdiPAZ, Madrid,, Spain
6Internal Medicine Department, Hospital Universitario Infanta Sofia, Madrid, Spain
7Pulmonology Department, Hospital Universitario La Paz, Institute for Health Research IdiPAZ, CIBERES. Medicine Department, Universidad Autonoma de Madrid, Spain
*Corresponding Author : Elena Villamanan, Pharmacy Department, Hospital Universitario La Paz, Institute for Health Research IdiPAZ, Medicine Department, Universidad Autonoma de Madrid, Spain, Email: selena.villamanan@salud.madrid.org

Received Date: Aug 11, 2022 / Published Date: Sep 12, 2022

Abstract

Background: Usefulness of colchicine in hospitalized COVID-19 patients with pneumonia has been compared with standard of care (SOC) in several studies around the world with many different results. Taken on account the variability of patient’s characteristics and their SOC according to the country, we carried out the following analysis in order to contribute with more data to the knowledge of this treatment.

Objective: To evaluate whether treatment with colchicine reduced the rate of death in COVID-19 hospitalized patients.Length of stay, differences in response by sex and age, response to colchicine according to inflammatory markers, comorbidity and concomitant drugs prescribed to treat these patients were also analyzed.

Methods: Real-world, controlled, retrospective study carried out in two tertiary hospitals in Spain. Outcomes werecompared in patients who received colchicine (colchicine group-CG) with those inpatients who did not (non-colchicine group-NCG). Controls were matched to the CG 1:1 by age (±2 years), sex and severity of the disease.

Results: 222 patients were evaluated (111 treated with colchicine), median age 79 years (66-87). There were 19(17.1%) deaths in the CG and in 32(29.4%) in the NCG (OR: 0.497;95%CI:0.261–0.946;p=0.031). A longer hospital stays in CG with respect to NCG (13[7-20] vs. 10 [6-15], respectively; p=0.019) was observed. Proportion of deaths were significantly higher in the NCG than in CG in patients≥ 70years (p=0.012). A greater benefit of colchicine treatment was detected for men even though our data did not reach significant differences. There were differences in deaths between the CG and NCG in patients with CRP high levels (p=0.046). 88.7% of patients had comorbidities, most frequently systemic hypertension, diabetes, COPD and cardiovascular disease, with no differences in deaths between both groups. Almost all patients received antimicrobials (91.9%) concomitantly, mainly azithromycin and ceftriaxone.We found differences in death rate between two groups in patients using antibiotics (38% in CG vs. 62% in NCG) (p=0.023).

Conclusion: Our findings support that colchicine may reduce mortality in COVID-19 hospitalized patients with pneumonia. These results indicate that, despite the available data, more RCTs are still needed in order to identify which patients hospitalized for COVID-19 pneumonia may benefit from this safe and inexpensive drug.

Citation: Villamanan E, Sobrino C, Carpio C, Mateos C, Larrubia Y, Zamarron E, et al. (2022) Colchicine and Covid-19: Could there still be Hope for this Old Low- Cost Drug?: Multicenter Observational Study in Hospitalized Patients. J Clin Infect Dis Pract, 7: 158.

Copyright: © 2022 Villamanan E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top